Michael Germuska

Michael Germuska

Auto-generated profile, based on publicly available information

Michael Germuska

Department of Radiology, University of California Davis Medical Center, Sacramento, USA

Research Focus & Metrics

Academic Career Length

22Years (2005-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2012 in NeuroImage
Verified
Journal Article
Closed access
DBD.P. Bulte
D.P. Bulte
MKM. Kelly
M. Kelly
MGM. Germuska
M. Germuska
JXJ. Xie
J. Xie
MCM.A. Chappell
M.A. Chappell
PJP. Jezzard
P. Jezzard

1 April 2011 in Journal of Clinical Oncology
Verified
Journal Article
Closed access
TYTimothy A. Yap
Timothy A. Yap
DODavid Olmos
David Olmos
ABAndre T. Brunetto
Andre T. Brunetto
NTNina Tunariu
Nina Tunariu
JBJorge Barriuso
Jorge Barriuso
JBJohann S. de Bono
Johann S. de Bono
Purpose: The hepatocyte growth factor/c-MET axis is implicated in tumor cell proliferation, survival, and angiogenesis. ARQ 197 is an oral, selective, non–adenosine triphosphate competitive c-MET inhibitor. A phase I trial of ARQ 197 was conducted to assess safety, tolerability, and target inhibition, including intratumoral c-MET signaling, apoptosis, and angiogenesis. Patients and Methods: Patients with solid tumors amenable to pharmacokinetic and pharmacodynamic studies using serial biopsies, dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI), and circulating endothelial cell (CEC) and circulating tumor cell (CTC) enumeration were enrolled. Results: Fifty-one patients received ARQ 197 at 100 to 400 mg twice per day. ARQ 197 was well tolerated, with the most common toxicities being grade 1 to 2 fatigue, nausea, and vomiting. Dose-limiting toxicities included grade 3 fatigue (200 mg twice per day; n = 1); grade 3 mucositis, palmar-plantar erythrodysesthesia, and hypokalemia (400 mg twice per day; n = 1); and grade 3 to 4 febrile neutropenia (400 mg twice per day, n = 2; 360 mg twice per day, n = 1). The recommended phase II dose was 360 mg twice per day. ARQ 197 systemic exposure was dose dependent and supported twice per day oral dosing. ARQ 197 decreased phosphorylated c-MET, total c-MET, and phosphorylated focal adhesion kinase and increased terminal deoxynucleotidyl transferase–mediated deoxyuridine triphosphate-biotin nick-end labeling (TUNEL) staining in tumor biopsies (n = 15). CECs decreased in 25 (58.1%) of 43 patients, but no significant changes in DCE-MRI parameters were observed after ARQ 197 treatment. Of 15 patients with detectable CTCs, eight (53.3%) had ≥ 30% decline in CTCs after treatment. Stable disease, as defined by Response Evaluation Criteria in Solid Tumors (RECIST), ≥ 4 months was observed in 14 patients, with minor regressions in gastric and Merkel cell cancers. Conclusion: ARQ 197 safely inhibited intratumoral c-MET signaling. Further clinical evaluation focusing on combination approaches, including an erlotinib combination in non–small-cell lung cancer, is ongoing.

23 August 2014 in Alzheimer's & Dementia
Verified
Journal Article
Closed access
SSSana Suri
Sana Suri
CMClare E. Mackay
Clare E. Mackay
MKMichael E. Kelly
Michael E. Kelly
MGMichael Germuska
Michael Germuska
ETElizabeth M. Tunbridge
Elizabeth M. Tunbridge
NFNicola Filippini
Nicola Filippini

1 December 2009 in American Journal of Roentgenology
Verified
Journal Article
Closed access
SRSophie F. Riches
Sophie F. Riches
GPGeoffrey S. Payne
Geoffrey S. Payne
VMVeronica A. Morgan
Veronica A. Morgan
SSSamir Sandhu
Samir Sandhu
CFCyril Fisher
Cyril Fisher
NDNandita M. Desouza
Nandita M. Desouza
OBJECTIVE. The purpose of this study was to compare apparent diffusion coefficients, metabolic ratios, and vascularity values within histologically defined prostate tumors with those in nontumor tissue to determine which functional parameter or combination of parameters is best for differentiating tumor from nontumor tissue.SUBJECTS AND METHODS. Twenty patients due for prostatectomy underwent endorectal MRI at 1.5 T. Transverse T2-weighted, diffusion-weighted, 2D chemical shift, and dynamic contrast-enhanced images were acquired. After prostatectomy, the gland was sectioned transversely. Fresh slices and stained whole-mount sections with histologically defined tumor outlines were photographed. The tumor outlines were mapped onto images, and the apparent diffusion coefficient (ADC), choline-to-citrate (Cho/cit) ratio, and vascularity of the histologically defined tumor, normal peripheral zone, and central gland were quantitatively measured. Area under the receiver operating characteristics (ROC) curve (Az)...

1 January 2019 in NeuroImage
Verified
Journal Article
Open access
MGM. Germuska
M. Germuska
HCH.L. Chandler
H.L. Chandler
RSR.C. Stickland
R.C. Stickland
CFC. Foster
C. Foster
FFF. Fasano
F. Fasano
RWR.G. Wise
R.G. Wise
Dual-calibrated fMRI is a multi-parametric technique that allows for the quantification of the resting oxygen extraction fraction (OEF), the absolute rate of cerebral metabolic oxygen consumption (CMRO2), cerebral vascular reactivity (CVR) and baseline perfusion (CBF). It combines measurements of arterial spin labelling (ASL) and blood oxygenation level dependent (BOLD) signal changes during hypercapnic and hyperoxic gas challenges. Here we propose an extension to this methodology that permits the simultaneous quantification of the effective oxygen diffusivity of the capillary network (DC). The effective oxygen diffusivity has the scope to be an informative biomarker and useful adjunct to CMRO2, potentially providing a non-invasive metric of microvascular health, which is known to be disturbed in a range of neurological diseases. We demonstrate the new method in a cohort of healthy volunteers (n = 19) both at rest and during visual stimulation. The effective oxygen diffusivity was found to be highly correlated with CMRO2 during rest and activation, consistent with previous PET observations of a strong correlation between metabolic oxygen demand and effective diffusivity. The increase in effective diffusivity during functional activation was found to be consistent with previously reported increases in capillary blood volume, supporting the notion that measured oxygen diffusivity is sensitive to microvascular physiology.

8 September 2005 in Cerebral Cortex
Verified
Journal Article
Open access
PDF file
MGMichael Germuska
Michael Germuska
SSSubhash Saha
Subhash Saha
JFJohn Fiala
John Fiala
HBHelen Barbas
Helen Barbas
Prefrontal pathways exert diverse effects in widespread cortical areas, issuing projections both to the middle layers and to layer I, which are anatomically and functionally distinct. Here we addressed the still unanswered question of whether cortical pathways that terminate in different layers are distinct at the synaptic level. We addressed this issue using as a model system the robust and functionally significant pathways from prefrontal areas 10 and 32 to superior temporal areas in rhesus monkeys. Boutons from prefrontal axons synapsing in the middle layers of superior temporal cortex were significantly larger than boutons synapsing in layer I. Most synapses were on spines in both layers, which are found on dendrites of excitatory neurons. The less prevalent synapses on smooth dendrites, characteristic of inhibitory interneurons, were more common in the middle cortical layers than in layer I. Bouton volume was linearly related to vesicular and mitochondrial content in both layers, though a subset of small boutons, found mostly in layer I, contained no mitochondria. The systematic laminar-specific presynaptic differences in stable cortical synapses in adult primates were independent of their origin in the functionally distinct prefrontal areas 10 and 32, or their destination in architectonically distinct superior temporal areas. This synaptic distinction suggests differences in efficacy of synaptic transmission and metabolic demands in laminar-specific pathways that may be selectively recruited in behavior.